Click here to close now.




















Welcome!

News Feed Item

Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014

LONDON, Aug. 25, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/703947/Aortic-Valve-Stenosis-Global-Clinical-Trials-Review-H2-2014.html

Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014" provides data on the Aortic Valve Stenosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Aortic Valve Stenosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Aortic Valve Stenosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Aortic Valve Stenosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20
Clinical Trials by Trial Status 21
Clinical Trials by End Point Status 22
Unaccomplished Trials of Aortic Valve Stenosis 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Aortic Valve Stenosis Therapeutics Clinical Trials 27
Prominent Drugs 29
Clinical Trial Profiles 30
Clinical Trial Overview of Top Companies 30
Edwards Lifesciences Corporation 30
Clinical Trial Overview of Edwards Lifesciences Corporation 30
CryoLife, Inc. 31
Clinical Trial Overview of CryoLife, Inc. 31
AstraZeneca PLC 32
Clinical Trial Overview of AstraZeneca PLC 32
Pfizer Inc. 33
Clinical Trial Overview of Pfizer Inc. 33
Merck & Co., Inc. 34
Clinical Trial Overview of Merck & Co., Inc. 34
Direct Flow Medical, Inc. 35
Clinical Trial Overview of Direct Flow Medical, Inc. 35
Cerenis Therapeutics SA 36
Clinical Trial Overview of Cerenis Therapeutics SA 36
A. Menarini Industrie Farmaceutiche Riunite Srl 37
Clinical Trial Overview of A. Menarini Industrie Farmaceutiche Riunite Srl 37
Clinical Trial Overview of Top Institutes / Government 38
National Heart, Lung, and Blood Institute 38
Clinical Trial Overview of National Heart, Lung, and Blood Institute 38
Erasmus MC 39
Clinical Trial Overview of Erasmus MC 39
Assistance Publique - Hopitaux de Paris 40
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 40
Washington University School of Medicine 41
Clinical Trial Overview of Washington University School of Medicine 41
Charles University 42
Clinical Trial Overview of Charles University 42
University of Edinburgh 43
Clinical Trial Overview of University of Edinburgh 43
Asan Medical Center 44
Clinical Trial Overview of Asan Medical Center 44
Helsinki University Central Hospital 45
Clinical Trial Overview of Helsinki University Central Hospital 45
Aarhus University Hospital 46
Clinical Trial Overview of Aarhus University Hospital 46
Sahlgrenska University Hospital 47
Clinical Trial Overview of Sahlgrenska University Hospital 47
Five Key Clinical Profiles 48
Appendix 69
Abbreviations 69
Definitions 69
Research Methodology 70
Secondary Research 70
About GlobalData 71
Contact Us 71
Disclaimer 71
Source 71

List of Tables
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Aortic Valve Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Aortic Valve Stenosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Aortic Valve Stenosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Aortic Valve Stenosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Aortic Valve Stenosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Aortic Valve Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Aortic Valve Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Phase, 2014* 19
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 20
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Aortic Valve Stenosis Therapeutics, Global, Suspended Clinical Trials, 2014* 23
Aortic Valve Stenosis Therapeutics, Global, Terminated Clinical Trials, 2014* 23
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 24
Aortic Valve Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 25
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 26
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Edwards Lifesciences Corporation, 2014* 30
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by CryoLife, Inc., 2014* 31
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 32
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 33
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 34
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Direct Flow Medical, Inc., 2014* 35
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Cerenis Therapeutics SA, 2014* 36
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by A. Menarini Industrie Farmaceutiche Riunite Srl, 2014* 37
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 38
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Erasmus MC, 2014* 39
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 40
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 41
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Charles University, 2014* 42
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Edinburgh, 2014* 43
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Asan Medical Center, 2014* 44
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Helsinki University Central Hospital, 2014* 45
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Aarhus University Hospital, 2014* 46
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sahlgrenska University Hospital, 2014* 47

List of Figures
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Aortic Valve Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Aortic Valve Stenosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Aortic Valve Stenosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Aortic Valve Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Aortic Valve Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 19
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 20
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 24
Aortic Valve Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 25
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 26
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 27
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
GlobalData Methodology 70


Read the full report:
Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/703947/Aortic-Valve-Stenosis-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that DataClear Inc. will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The DataClear ‘BlackBox’ is the only solution that moves your PC, browsing and data out of the United States and away from prying (and spying) eyes. Its solution automatically builds you a clean, on-demand, virus free, new virtual cloud based PC outside of the United States, and wipes it clean...
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
Any Ops team trying to support a company in today’s cloud-connected world knows that a new way of thinking is required – one just as dramatic than the shift from Ops to DevOps. The diversity of modern operations requires teams to focus their impact on breadth vs. depth. In his session at DevOps Summit, Adam Serediuk, Director of Operations at xMatters, Inc., will discuss the strategic requirements of evolving from Ops to DevOps, and why modern Operations has begun leveraging the “NoOps” approa...
While many app developers are comfortable building apps for the smartphone, there is a whole new world out there. In his session at @ThingsExpo, Narayan Sainaney, Co-founder and CTO of Mojio, will discuss how the business case for connected car apps is growing and, with open platform companies having already done the heavy lifting, there really is no barrier to entry.
SYS-CON Events announced today that G2G3 will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based on a collective appreciation for user experience, design, and technology, G2G3 is uniquely qualified and motivated to redefine how organizations and people engage in an increasingly digital world.
As more intelligent IoT applications shift into gear, they’re merging into the ever-increasing traffic flow of the Internet. It won’t be long before we experience bottlenecks, as IoT traffic peaks during rush hours. Organizations that are unprepared will find themselves by the side of the road unable to cross back into the fast lane. As billions of new devices begin to communicate and exchange data – will your infrastructure be scalable enough to handle this new interconnected world?
SYS-CON Events announced today that Micron Technology, Inc., a global leader in advanced semiconductor systems, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Micron’s broad portfolio of high-performance memory technologies – including DRAM, NAND and NOR Flash – is the basis for solid state drives, modules, multichip packages and other system solutions. Backed by more than 35 years of tech...
This Enterprise Strategy Group lab validation report of the NEC Express5800/R320 server with Intel® Xeon® processor presents the benefits of 99.999% uptime NEC fault-tolerant servers that lower overall virtualized server total cost of ownership. This report also includes survey data on the significant costs associated with system outages impacting enterprise and web applications. Click Here to Download Report Now!
SYS-CON Events announced today that Pythian, a global IT services company specializing in helping companies leverage disruptive technologies to optimize revenue-generating systems, has been named “Bronze Sponsor” of SYS-CON's 17th Cloud Expo, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Founded in 1997, Pythian is a global IT services company that helps companies compete by adopting disruptive technologies such as cloud, Big Data, advance...
SYS-CON Events announced today the Containers & Microservices Bootcamp, being held November 3-4, 2015, in conjunction with 17th Cloud Expo, @ThingsExpo, and @DevOpsSummit at the Santa Clara Convention Center in Santa Clara, CA. This is your chance to get started with the latest technology in the industry. Combined with real-world scenarios and use cases, the Containers and Microservices Bootcamp, led by Janakiram MSV, a Microsoft Regional Director, will include presentations as well as hands-on...
Cloud and datacenter migration innovator AppZero has joined the Microsoft Enterprise Cloud Alliance Program. AppZero is a fast, flexible way to move Windows Server applications from any source machine – physical or virtual – to any destination server, in any cloud or datacenter, using its patented container technology. AppZero’s container is also called a Virtual Application Appliance (VAA). To facilitate Microsoft Azure onboarding, AppZero has two purpose-built offerings: AppZero SP for Azure,...
Organizations from small to large are increasingly adopting cloud solutions to deliver essential business services at a much lower cost. According to cyber security experts, the frequency and severity of cyber-attacks are on the rise, causing alarm to businesses and customers across a variety of industries. To defend against exploits like these, a company must adopt a comprehensive security defense strategy that is designed for their business. In 2015, organizations such as United Airlines, Sony...
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Consumer IoT applications provide data about the user that just doesn’t exist in traditional PC or mobile web applications. This rich data, or “context,” enables the highly personalized consumer experiences that characterize many consumer IoT apps. This same data is also providing brands with unprecedented insight into how their connected products are being used, while, at the same time, powering highly targeted engagement and marketing opportunities. In his session at @ThingsExpo, Nathan Trel...
Red Hat is investing in Tesora, the number one contributor to OpenStack Trove Database as a Service (DBaaS) also ranked among the top 20 companies contributing to OpenStack overall. Tesora, the company bringing OpenStack Trove Database as a Service (DBaaS) to the enterprise, has announced that Red Hat and others have invested in the company as a part of Tesora's latest funding round. The funding agreement expands on the ongoing collaboration between Tesora and Red Hat, which dates back to Febr...